EMERYVILLE, Calif., March 6, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of infections, today announced that Ron Najafi, Chief Executive Officer, will present at the 24th Annual ROTH Conference, held March 11-14, 2012, in Dana Point, California. Later that month, Tom Paulson, Chief Financial Officer, will present at the 5th Annual Maxim Group Growth Conference, held on March 26, 2012, in New York, New York.
Dr. Najafi and Mr. Paulson will be available to respond to questions and to participate in one-on-one meetings with investors attending the ROTH conference, and Mr. Paulson will be available at the Maxim conference.
Event 24th Annual ROTH Conference Date Monday, March 12, 2012 Time 1:00pm PT Place Salon 1; The Ritz Carlton Hotel, Dana Point, CA
Event 5th Annual Maxim Group Growth Conference Date Monday, March 26, 2012 Time 9:30am ET Place Edison & Wintergarden; Grand Hyatt Hotel, New York, NY
About NovaBay Pharmaceuticals, Inc.
Going Beyond Antibiotics
NovaBay Pharmaceuticals is an advanced clinical-stage biotechnology company whose focus is on developing two distinct categories of product offerings to address large unmet therapeutic needs of the global anti-infective market.
Aganocide® Compounds
NovaBay's first-in-class Aganocide® compounds, led by NVC-422, are highly-patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Similar to the mechanism of action of the human white blood cell which they mimic, Aganocides possess the critical attribute of a low likelihood that bacteria or viruses will be able to develop resistance. Having already demonstrating therapeutic proof of concept in three advanced Phase 2 clinical studies, these compounds are uniquely suited to treat and prevent a wide range of local, non-systemic infections in three large therapeutic markets:
- Dermatology – the focus is on developing a gel formulation of NVC-422 for large global market for treating the highly contagious skin infection, impetigo. Current product offerings give rise to resistance and not effective against MRSA. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world.
- Ophthalmology – the goal is to develop an eye drop for viral conjunctivitis; for which there is currently no FDA approved treatment available.
- Urology – Aim is to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422.
NeutroPhase®
NovaBay is also developing another class of molecule, NeutroPhase®, for advanced wound care. With a unique chemical composition and mechanism of action from the Aganocides, NeutroPhase is well-suited for use in treating the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers. Additionally, unlike other product offering in this therapeutic area, NeutroPhase is the only patented pure hypochlorous acid solution available. Having already received two 510(K) clearances from the U.S. Food and Drug Administration, NovaBay has begun securing commercial partnerships in select geographic markets around the world. In January, 2012, NovaBay announced it had entered into a strategic marketing agreement for NeutroPhase with Pioneer Pharma Co., Ltd., a Shanghai-based company that markets high-end pharmaceutical products into China. NovaBay expects to announce additional marketing agreements during 2012.
For additional information, visit: www.novabaypharma.com.